

NEXLETOL- bempedoic acid tablet, film coated

Esperion Therapeutics, Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use NEXLETOL® safely and effectively. See full prescribing information for NEXLETOL.

NEXLETOL (bempedoic acid) tablets, for oral use

Initial U.S. Approval: 2020

RECENT MAJOR CHANGES

Indications and Usage (1)	03/2024
Dosage and Administration (2.1)	03/2024
Contraindications (4)	03/2024
Warnings and Precautions (5.1, 5.2)	03/2024

INDICATIONS AND USAGE

NEXLETOL, an adenosine triphosphate-citrate lyase (ACL) inhibitor, is indicated:

- To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with:
 - established cardiovascular disease (CVD), or
 - a high risk for a CVD event but without established CVD. (1)
- As an adjunct to diet, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). (1)

DOSAGE AND ADMINISTRATION

Administer 180 mg orally once daily with or without food. (2.1)

DOSAGE FORMS AND STRENGTHS

Tablets: 180 mg (3)

CONTRAINDICATIONS

History of a serious hypersensitivity reaction to bempedoic acid or any of the excipients in NEXLETOL. (4)

WARNINGS AND PRECAUTIONS

Hyperuricemia: Elevations in serum uric acid have occurred. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate. (5.1)

Tendon Rupture: Tendon rupture has occurred. Discontinue NEXLETOL at the first sign of tendon rupture. Avoid NEXLETOL in patients who have a history of tendon disorders or tendon rupture. (5.2)

ADVERSE REACTIONS

Common adverse reactions in the (6.1):

- Primary hyperlipidemia trials (incidence \geq 2% and more frequent than placebo) were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes.
- Cardiovascular outcomes trial (incidence \geq 2% and 0.5% greater than placebo) were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis.

To report SUSPECTED ADVERSE REACTIONS, contact Esperion at 833-377-7633 (833 ESPRMED) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- *Simvastatin:* Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg. (7)
- *Pravastatin:* Avoid concomitant use of NEXLETOL with pravastatin greater than 40 mg. (7)

USE IN SPECIFIC POPULATIONS

- *Pregnancy:* Based on mechanism of action, may cause fetal harm. (8.1)
- *Lactation:* Breastfeeding is not recommended with NEXLETOL. (8.2)

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Hyperuricemia

5.2 Tendon Rupture

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Postmarketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Renal Impairment

8.7 Hepatic Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

14.1 Cardiovascular Outcomes Trial in Adults With CVD or at High Risk for CVD

14.2 Primary Hyperlipidemia Trials in Adults

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

NEXLETOL is indicated:

- To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with:
 - established cardiovascular disease (CVD), or
 - a high risk for a CVD event but without established CVD.
- As an adjunct to diet, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage

The recommended dosage of NEXLETOL is 180 mg administered orally once daily. NEXLETOL can be taken with or without food.

After initiation of NEXLETOL, analyze lipid levels within 8 to 12 weeks.

3 DOSAGE FORMS AND STRENGTHS

NEXLETOL is available as:

- Tablets: 180 mg, white to off-white, oval shaped, debossed with "180" on one side and "ESP" on the other side.

4 CONTRAINDICATIONS

NEXLETOL is contraindicated in patients with a prior serious hypersensitivity reaction to bempedoic acid or any of the excipients in NEXLETOL. Serious hypersensitivity reactions, such as angioedema, have occurred [see *Adverse Reactions (6.2)*].

5 WARNINGS AND PRECAUTIONS

5.1 Hyperuricemia

NEXLETOL inhibits renal tubular OAT2 and may increase blood uric acid levels [see *Clinical Pharmacology (12.3)*]. In the primary hyperlipidemia trials [see *Clinical Studies (14.2)*], 26% of NEXLETOL-treated patients with normal baseline uric acid values (versus 9.5% placebo) experienced hyperuricemia one or more times, and 3.5% of patients experienced clinically significant hyperuricemia reported as an adverse reaction (versus 1.1% placebo). Increases in uric acid levels usually occurred within the first 4 weeks of treatment initiation, persisted throughout treatment, and returned to baseline following discontinuation of treatment. After 12 weeks of treatment, the mean placebo-adjusted increase in uric acid compared to baseline was 0.8 mg/dL for patients treated with NEXLETOL. In the cardiovascular outcomes trial [see *Clinical Studies (14.1)*], 16.4% of NEXLETOL-treated patients experienced clinically significant hyperuricemia reported as an adverse reaction (versus 8.2% placebo).

Elevated blood uric acid may lead to the development of gout. In the primary hyperlipidemia trials, gout was reported in 1.5% of patients treated with NEXLETOL and 0.4% of patients treated with placebo. In the cardiovascular outcomes trial, gout was reported in 3.2% of patients treated with NEXLETOL and 2.2% treated with placebo.

Advise patients to contact their healthcare provider if symptoms of hyperuricemia occur. Assess serum uric acid when clinically indicated. Monitor patients for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.

5.2 Tendon Rupture

NEXLETOL is associated with an increased risk of tendon rupture or injury. In the primary hyperlipidemia trials [see *Clinical Studies (14.2)*], tendon rupture occurred in 0.5% of patients treated with NEXLETOL versus 0% of placebo-treated patients and involved the rotator cuff (the shoulder), biceps tendon, or Achilles tendon. Tendon rupture occurred within weeks to months of starting NEXLETOL. In the cardiovascular outcomes trial [see *Clinical Studies (14.1)*], tendon rupture events occurred in 1.2% of NEXLETOL-treated patients versus 0.9% of placebo-treated patients. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders.

Discontinue NEXLETOL immediately if the patient experiences rupture of a tendon. Consider discontinuing NEXLETOL if the patient experiences joint pain, swelling, or inflammation. Advise patients to rest at the first sign of tendinitis or tendon rupture and to contact their healthcare provider if tendinitis or tendon rupture symptoms occur. Consider alternative therapy in patients with a history of tendon disorders or tendon rupture.

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Hyperuricemia [see *Warnings and Precautions (5.1)*]
- Tendon Rupture [see *Warnings and Precautions (5.2)*]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The data in Table 1 reflect exposure to NEXLETOL in two placebo-controlled primary hyperlipidemia trials that included 2,009 patients treated with NEXLETOL for 52 weeks (median treatment duration of 52 weeks) [see *Clinical Studies (14.2)*]. The mean age for NEXLETOL-treated patients was 65 years, 29% were female, 95% were White, 3% were Black or African American, 1% were Asian, and 1% were other races; 3% identified as Hispanic or Latino ethnicity. All patients received NEXLETOL 180 mg orally once daily plus maximally tolerated statin therapy alone or in combination with other lipid-lowering therapies. At baseline, 97% of patients had CVD and about 4% had a diagnosis of HeFH. Patients on simvastatin 40 mg/day or higher were excluded from the trials.

In the primary hyperlipidemia trials, adverse reactions led to discontinuation of treatment in 11% of NEXLETOL-treated patients and 8% of placebo-treated patients. The most common reasons for NEXLETOL treatment discontinuation were muscle spasms (0.5% versus 0.3% placebo), diarrhea (0.4% versus 0.1% placebo), and pain in extremity (0.3% versus 0.0% placebo). Adverse reactions reported in at least 2% of NEXLETOL-treated patients and more frequently than in placebo-treated patients are shown in Table 1.

Table 1. Adverse Reactions ($\geq 2\%$ and greater than placebo) in NEXLETOL-Treated Patients with Primary Hyperlipidemia and CVD or HeFH (Trials 2 and 3)

Adverse Reaction	Placebo* (N = 999) %	NEXLETOL* (N = 2,009) %
Upper respiratory tract infection	4.0	4.5
Muscle spasms	2.3	3.6
Hyperuricemia [†]	1.1	3.5
Back pain	2.2	3.3
Abdominal pain or discomfort [†]	2.2	3.1
Bronchitis	2.5	3.0
Pain in extremity	1.7	3.0
Anemia	1.9	2.8
Elevated liver enzymes [†]	0.8	2.1

* Background therapy included statin and \pm other lipid-lowering therapies

† Grouped term that includes other related terms

In the cardiovascular outcomes trial, in which 7,001 patients were exposed to NEXLETOL and 6,964 patients were exposed to placebo for a median of 3.1 years [see *Clinical Studies, (14.1)*], adverse reactions led to discontinuation of treatment in 11% of NEXLETOL-treated patients and 10% of placebo-treated patients. Adverse reactions reported in at least 2% of NEXLETOL-treated patients and 0.5% greater than placebo are shown in Table 2.

Table 2. Adverse Reactions ($\geq 2\%$ and 0.5% greater than placebo) in NEXLETOL-Treated Patients with CVD or at High Risk for CVD (Trial 1)

Adverse Reaction	Placebo (N=6,964) %	NEXLETOL (N=7,001) %
Hyperuricemia*	8	16
Renal impairment [†]	9	11
Anemia	4	5
Elevated liver enzymes*	3	4
Muscle spasms	3	4

Gout	2	3
Cholelithiasis	1	2

* Grouped term that includes other related terms

† Renal impairment includes laboratory related terms including glomerular filtration rate decreased, blood creatinine increased and hematuria

Other Adverse Reactions

Tendon Rupture

In the hyperlipidemia trials, tendon rupture occurred in 0.5% of NEXLETOL-treated patients versus 0% of placebo-treated patients. In the cardiovascular outcomes trial, tendon rupture events occurred in 1.2% of NEXLETOL-treated patients versus 0.9% of placebo-treated patients.

Gout

In the hyperlipidemia trials, gout occurred in 1.5% of NEXLETOL-treated patients versus 0.4% of placebo-treated patients. In the cardiovascular outcomes trial, gout occurred in 3.2% of NEXLETOL-treated patients versus 2.2% of placebo-treated patients.

Laboratory Tests

NEXLETOL was associated with persistent changes in multiple laboratory tests that occurred within the first 4 weeks of treatment and returned to baseline following discontinuation of treatment.

Increase in Creatinine and Blood Urea Nitrogen

In the hyperlipidemia trials, there was a mean increase in serum creatinine of 0.05 mg/dL compared to baseline with NEXLETOL at Week 12. Approximately 3.8% of patients treated with NEXLETOL had blood urea nitrogen values that doubled (versus 1.5% placebo), and about 2.2% of patients had creatinine values that increased by 0.5 mg/dL (versus 1.1% placebo). In the cardiovascular outcomes trial, 7.1% of patients had creatinine values that increased by 0.5 mg/dL (versus 5.5% placebo) and 9.5% of patients in the NEXLETOL group had BUN values that increased $\geq 2\times$ baseline (versus 6.2% placebo).

Decrease in Hemoglobin and Leukocytes

In the hyperlipidemia trials, approximately 5.1% of patients treated with NEXLETOL (versus 2.3% placebo) had decreases in hemoglobin levels of 2 or more g/dL and below the lower limit of normal on one or more occasion. Anemia was reported in 2.8% of patients treated with NEXLETOL and 1.9% of patients treated with placebo. Approximately 9.0% of NEXLETOL-treated patients with normal baseline leukocyte count had a decrease to less than the lower limit of normal on one or more occasion (versus 6.7% placebo). Leukocyte decrease was generally asymptomatic and did not require medical intervention. In the hyperlipidemia trials, there was a small imbalance in skin or soft tissue infections, including cellulitis (0.8% versus 0.4%), but there was no imbalance in other infections.

In the cardiovascular outcomes trial, 10.8% of patients (versus 7.4% placebo) had a decrease in hemoglobin of 2 or more g/dL and below the lower limit of normal. Anemia was reported in 4.7% of patients treated with NEXLETOL and 3.9% of patients treated with placebo. There were 9.3% of NEXLETOL-treated patients with a leukocyte count

below the lower limit of normal (and normal at baseline) at any point (versus 6.8% placebo).

Increase in Platelet Count

In the hyperlipidemia trials, approximately 10.1% of patients (versus 4.7% placebo) had increases in platelet counts of $100 \times 10^9/L$ or more on one or more occasion. In the cardiovascular outcomes trial, 18.6% of patients in the NEXLETOL-treated group (versus 10.2% placebo) had an increase in platelet count of $100 \times 10^9/L$ or more. Platelet count increase was asymptomatic and did not result in increased risk for thromboembolic events.

Increase in Liver Enzymes

In the hyperlipidemia trials, increases in hepatic transaminases (AST and/or ALT) were observed with NEXLETOL. In most cases, the elevations were transient and resolved or improved with continued therapy or after discontinuation of therapy. Increases to more than $3 \times$ the upper limit of normal (ULN) in AST occurred in 1.4% of patients treated with NEXLETOL versus 0.4% of placebo patients, and increases to more than $5 \times$ ULN occurred in 0.4% of NEXLETOL-treated versus 0.2% of placebo-treated patients. Increases in ALT occurred with similar incidence between NEXLETOL- and placebo-treated patients. Elevations in transaminases were generally asymptomatic and not associated with elevations $\geq 2 \times$ ULN in bilirubin or with cholestasis.

In the cardiovascular outcomes trial, the incidence of repeated and confirmed ALT and/or AST $>3 \times$ ULN was 1.6% in the NEXLETOL-treated group (versus 1.0% placebo). A higher percentage of patients in the NEXLETOL-treated group had hepatic enzyme elevations versus placebo (4.5% versus 3.0%, respectively).

Increase in Creatine Kinase

In the hyperlipidemia trials, approximately 1.0% of patients (versus 0.6% placebo) had elevations of CK levels of 5 or more times the normal value on one or more occasions, and 0.4% of patients (versus 0.2% placebo) had elevations of CK levels of 10 or more times.

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of NEXLETOL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders: Hypersensitivity reactions including: angioedema, wheezing, rash, and urticaria.

7 DRUG INTERACTIONS

Table 3 includes a list of drugs with clinically important drug interactions when administered concomitantly with NEXLETOL and instructions for preventing or managing them.

Table 3. Clinically Important Drug Interactions with NEXLETOL

Simvastatin	
<i>Clinical Impact:</i>	Concomitant use of NEXLETOL with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy [see <i>Clinical Pharmacology (12.3)</i>].
<i>Intervention:</i>	Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg.
Pravastatin	
<i>Clinical Impact:</i>	Concomitant use of NEXLETOL with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy [see <i>Clinical Pharmacology (12.3)</i>].
<i>Intervention:</i>	Avoid concomitant use of NEXLETOL with pravastatin greater than 40 mg.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Discontinue NEXLETOL when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.

There are insufficient data on NEXLETOL use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, bempedoic acid was not teratogenic in rats and rabbits when administered at doses resulting in exposures up to 11 and 12 times, respectively, the human exposures at the maximum clinical dose, based on AUC (see *Data*). NEXLETOL decreases cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol; therefore, NEXLETOL may cause fetal harm when administered to pregnant women based on the mechanism of action [see *Clinical Pharmacology (12.1)*]. In addition, treatment of hyperlipidemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Report pregnancies to the Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633.

Data

Animal Data

Bempedoic acid was not teratogenic when given orally at doses of 60 and 80 mg/kg/day,

resulting in 11 and 12 times the systemic exposure in humans at the maximum recommended human dose (MRHD) of 180 mg to pregnant rats and rabbits, respectively. In an embryofetal development study in rats, bempedoic acid was given orally to pregnant rats at 10, 30, and 60 mg/kg/day during the period of organogenesis from gestation day 6 to 17. There were increases in the incidence of non-adverse fetal skeletal variations (bent long bones and bent scapula and incomplete ossification) at doses ≥ 10 mg/kg/day (less than the clinical exposure) in the absence of maternal toxicity. At maternally toxic doses, bempedoic acid caused decreases in the numbers of viable fetuses, increases in post-implantation loss, and increased total resorptions at 60 mg/kg/day (11 times MRHD) and reduced fetal body weight at ≥ 30 mg/kg/day (4 times the MRHD). No adverse development effects were observed when bempedoic acid was given to pregnant rabbits during the period of organogenesis (gestation day 6 to 18) at doses up to 80 mg/kg/day (12 times MRHD).

In a pre- and post-natal development study in pregnant rats given oral doses of bempedoic acid at 5, 10, 20, 30 and 60 mg/kg/day throughout pregnancy and lactation (gestation day 6 to lactation day 20), there were adverse effects on delivery in the presence of maternal toxicity, including: increases in stillborn pups, reductions in numbers of live pups, pup survival, pup growth and slight delays in learning and memory at ≥ 10 mg/kg/day (at exposures equivalent to the MRHD).

8.2 Lactation

Risk Summary

There is no information regarding the presence of NEXLETOL in human or animal milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. NEXLETOL decreases cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol and may cause harm to the breastfed infant. Because of the potential for serious adverse reactions in a breastfed infant, based on the mechanism of action, advise patients that breastfeeding is not recommended during treatment with NEXLETOL [*see Use in Specific Populations (8.1), Clinical Pharmacology (12.1)*].

8.4 Pediatric Use

The safety and effectiveness of NEXLETOL have not been established in pediatric patients.

8.5 Geriatric Use

Of the 3,009 adult patients in the primary hyperlipidemia trials of NEXLETOL, 1,753 (58%) were 65 years of age and older, while 478 (16%) were 75 years of age and older.

Of the 13,970 adult patients in the cardiovascular outcomes trial [*see Clinical Studies (14.2)*], 8,204 (59%) were 65 years of age and older, while 2,107 (15%) were 75 years of age and older.

No overall differences in safety or effectiveness of NEXLETOL have been observed between patients 65 years of age and older and younger adult patients.

8.6 Renal Impairment

No dosage adjustment is necessary in patients with mild or moderate renal impairment.

There is limited experience with NEXLETOL in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), and NEXLETOL has not been studied in patients with end-stage renal disease (ESRD) receiving dialysis [see *Clinical Pharmacology (12.3)*].

8.7 Hepatic Impairment

No dosage adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A or B) [see *Clinical Pharmacology (12.3)*]. Patients with severe hepatic impairment (Child-Pugh C) have not been studied.


10 OVERDOSAGE

There is no clinical experience with NEXLETOL overdose. In the event of an overdose, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.

11 DESCRIPTION

NEXLETOL tablets, for oral use, contain bempedoic acid, an adenosine triphosphate-citrate lyase (ACL) inhibitor. The chemical name for bempedoic acid is 8-hydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid. The molecular formula is C₁₉H₃₆O₅, and the molecular weight is 344.5 grams per mole. Bempedoic acid is a white to off-white crystalline powder that is highly soluble in ethanol, isopropanol and pH 8 phosphate buffer, and insoluble in water and aqueous solutions below pH 5.

Structural formula:



Each film-coated tablet of NEXLETOL contains 180 mg of bempedoic acid and the following inactive ingredients: colloidal silicon dioxide, hydroxyl propyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The film coating comprises of partially hydrolyzed polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Bempedoic acid and its active metabolite, ESP15228, require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1) to ETC-1002-CoA and ESP15228-CoA, respectively. ACSVL1 is expressed primarily in the liver. Inhibition of ACL by ETC-1002-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of low-density lipoprotein receptors.

12.2 Pharmacodynamics

Administration of bempedoic acid alone, or in combination with other lipid modifying agents, decreases LDL-C, non-high density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (apo B), and total cholesterol (TC) in patients with hyperlipidemia.

Cardiac Electrophysiology

At a dose of 240 mg (1.3 times the approved recommended dose), bempedoic acid does not prolong the QT interval to any clinically relevant extent.

12.3 Pharmacokinetics

Bempedoic acid pharmacokinetic parameters are presented as the mean [standard deviation \pm (SD)] unless otherwise specified. The steady-state maximum plasma concentration (C_{max}) and area under the curve (AUC) following multiple-dose administration of bempedoic acid at 180 mg/day were 20.6 ± 6.1 $\mu\text{g/mL}$ and 289.0 ± 96.4 $\mu\text{g}\cdot\text{h/mL}$, respectively. Bempedoic acid steady-state pharmacokinetics were generally linear over a range of > 60 mg to 220 mg (approximately 33% to 122% of the recommended dosage of 180 mg daily). There were no time-dependent changes in bempedoic acid pharmacokinetics following repeat administration at the recommended dosage, and bempedoic acid steady-state was achieved after 7 days. The mean accumulation ratio was approximately 2.3-fold.

The steady-state C_{max} and AUC of the active metabolite (ESP15228) of bempedoic acid were 2.8 ± 0.9 $\mu\text{g/mL}$ and 51.2 ± 17.2 $\mu\text{g}\cdot\text{h/mL}$, respectively. ESP15228 likely made a minor contribution to the overall clinical activity of bempedoic acid based on systemic exposure, relative potency, and pharmacokinetic properties.

Absorption

Pharmacokinetic data indicate that bempedoic acid is absorbed with a median time to maximum concentration of 3.5 hours when administered as NEXLETOL 180 mg tablets.

Effect of Food

Concomitant food administration had no effect on the oral bioavailability of bempedoic acid.

Distribution

The bempedoic acid apparent volume of distribution (V/F) was 18 L. Plasma protein binding of bempedoic acid, its glucuronide and its active metabolite, ESP15228, were 99.3%, 98.8% and 99.2%, respectively. Bempedoic acid does not partition into blood cells.

Elimination

The steady-state clearance (CL/F) of bempedoic acid was 11.2 mL/min after once-daily dosing; renal clearance of unchanged bempedoic acid represented less than 2% of total clearance. The mean \pm SD half-life for bempedoic acid in humans was 21 ± 11 hours at steady-state.

Metabolism

The primary route of elimination for bempedoic acid is through metabolism of the acyl glucuronide. Bempedoic acid is also reversibly converted to an active metabolite (ESP15228) based on aldo-keto reductase activity observed *in vitro* from human liver. Mean plasma AUC metabolite/parent drug ratio for ESP15228 following repeat-dose administration was 18% and remained constant over time. Both compounds are converted to inactive glucuronide conjugates *in vitro* by UGT2B7. Bempedoic acid, ESP15228 and their respective conjugated forms were detected in plasma with bempedoic acid accounting for the majority (46%) of the AUC_{0-48h} and its glucuronide being the next most prevalent (30%). ESP15228 and its glucuronide represented 10% and 11% of the plasma AUC_{0-48h}, respectively.

Excretion

Following single oral administration of 240 mg of bempedoic acid (1.3 times the approved recommended dose), approximately 70% of the total dose (bempedoic acid and its metabolites) was recovered in urine, primarily as the acyl glucuronide conjugate of bempedoic acid, and approximately 30% was recovered in feces. Less than 5% of the administered dose was excreted as unchanged bempedoic acid in feces and urine combined.

Specific Populations

Patients with Renal Impairment

Pharmacokinetics of bempedoic acid was evaluated in a single-dose pharmacokinetic study in subjects with varying degrees of renal function. The mean bempedoic acid AUC in subjects with mild renal impairment (n = 8) were 1.5-fold higher compared to those with normal renal function (n = 6). Relative to those with normal renal function, mean bempedoic acid AUCs were higher in patients with moderate (n = 5) or severe (n = 5) renal impairment by 2.3-fold and 2.4-fold, respectively.

A population pharmacokinetic analysis was performed on pooled data from all clinical trials (n = 2,261) to further evaluate the effects of renal function on the steady-state AUC of bempedoic acid. Compared to patients with normal renal function, the mean bempedoic acid exposures were higher in patients with mild or moderate renal impairment by 1.4-fold (90% CI: 1.3, 1.4) and 1.9-fold (90% CI: 1.7, 2.0), respectively. These differences were not clinically significant. Clinical studies of NEXLETOL did not include patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²) or patients with ESRD on dialysis [see *Use in Specific Populations (8.6)*].

Patients with Hepatic Impairment

The pharmacokinetics of bempedoic acid and its metabolite (ESP15228) was studied in patients with normal hepatic function or mild or moderate hepatic impairment (Child-Pugh A or B) following a single dose (n = 8/group). Compared to patients with normal hepatic function, the bempedoic acid mean C_{max} and AUC were decreased by 11% and

22%, respectively, in patients with mild hepatic impairment and by 14% and 16%, respectively, in patients with moderate hepatic impairment. Compared to patients with normal hepatic function, the ESP15228 mean C_{max} and AUC were decreased by 13% and 23%, respectively, in patients with mild hepatic impairment and by 24% and 36%, respectively, in patients with moderate hepatic impairment. This is not expected to result in lower efficacy.

Bempedoic acid was not studied in patients with severe hepatic impairment (Child-Pugh C) [see *Use in Specific Populations (8.7)*].

Other Specific Populations

The pharmacokinetics of bempedoic acid were not affected by age, gender, race, or weight.

Drug Interaction Studies

Cytochrome P450 Substrates

In vitro metabolic interaction studies suggest that bempedoic acid, as well as its active metabolite and glucuronide forms are not metabolized by and do not interact with cytochrome P450 enzymes.

Transporter-mediated Drug Interactions

In vitro drug interaction studies suggest bempedoic acid, as well as its active metabolite and glucuronide form, are not substrates of commonly characterized drug transporters with the exception of bempedoic acid glucuronide, which is an OAT3 substrate.

Bempedoic acid weakly inhibits OAT3 at high multiples of clinically relevant concentrations, and bempedoic acid and its glucuronide weakly inhibit OATP1B1, and OATP1B3 at clinically relevant concentrations. Bempedoic acid weakly inhibits OAT2 *in vitro*, which is likely the mechanism responsible for minor elevations in serum creatinine and uric acid [see *Adverse Reactions (6.1)*].

Probenecid

Administration of bempedoic acid 180 mg with steady-state probenecid resulted in a 1.7- and a 1.2-fold increase in bempedoic acid AUC and C_{max} , respectively. AUC and C_{max} for bempedoic acid active metabolite (ESP15228) were increased 1.9- and 1.5-fold, respectively. These elevations are not clinically meaningful and do not impact dosing recommendations.

Statins

The pharmacokinetic interactions between bempedoic acid (at systemic exposure relevant to the indicated CVD population) and simvastatin 20 mg, atorvastatin 10 mg, pravastatin 40 mg, and rosuvastatin 10 mg were evaluated in clinical trials.

Simvastatin: Administration of simvastatin 20 mg with 240 mg of bempedoic acid or 40 mg with 180 mg of bempedoic acid in healthy subjects at steady-state resulted in approximately 2-fold (91% for 20 mg and 96% for 40 mg) and 1.5-fold (54% for 20 mg and 52% for 40 mg) increases in simvastatin acid AUC and C_{max} , respectively [see *Drug Interactions (7)*].

Pravastatin: Administration of pravastatin 40 mg with steady-state bempedoic acid 240 mg in healthy subjects resulted in 99% (2-fold) and 104% (2-fold) increases in pravastatin acid AUC and C_{max} , respectively [see *Drug Interactions (7)*].

Atorvastatin and Rosuvastatin: Elevations of 1.7-fold in AUC of atorvastatin, and rosuvastatin and/or their major metabolites were observed, suggesting a weak interaction. These elevations were generally within the individual statin exposures and do not impact dosing recommendations.

Ezetimibe

Increases in AUC and C_{max} for ezetimibe were less than 20% when a single dose of ezetimibe was taken with steady-state bempedoic acid. Total ezetimibe (ezetimibe and its glucuronide form) and ezetimibe glucuronide AUC and C_{max} increased approximately 1.6- and 1.8-fold, respectively. These elevations are not clinically meaningful and do not impact dosing recommendations.

Warfarin

In vitro studies indicate that bempedoic acid is not an inhibitor or inducer of CYP2C9. Because warfarin is primarily eliminated through CYP2C9, its pharmacokinetics is not expected to be altered by bempedoic acid.

Other

Bempedoic acid had no effect on the pharmacokinetics of metformin or the oral contraceptive Ortho-Novum 1/35.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Bempedoic acid was negative for mutagenicity in an *in vitro* Ames assay and negative for clastogenicity in the *in vitro* human lymphocyte chromosome aberration assay. Bempedoic acid was negative in both *in vivo* mouse micronucleus and *in vivo* rat bone marrow micronucleus/liver comet assay. In a 2-year rat carcinogenicity study, Wistar rats were given oral doses of bempedoic acid at 3, 10 and 30 mg/kg/day. An increased incidence of liver hepatocellular adenomas and hepatocellular adenomas combined with carcinomas, thyroid gland follicular cell adenoma and follicular cell adenomas combined with carcinomas, and pancreatic islet cell adenomas combined with carcinomas were observed in male rats at the dose of 30 mg/kg/day (exposure equivalent to the maximum recommended human dose (MRHD), based on AUC). In a 2-year mice carcinogenicity study, CD-1 mice were given oral doses of bempedoic acid at 25, 75 and 150 mg/kg/day. Bempedoic acid-related increases in the incidence of liver hepatocellular adenomas, hepatocellular carcinomas and hepatocellular adenomas combined with carcinomas in male mice were observed at 75 and 150 mg/kg/day (exposures equivalent to the MRHD). Observations of liver and thyroid tumors are consistent with PPAR alpha agonism in rodents. The human relevance of pancreatic islet cell tumor findings is unknown.

In fertility and early embryofetal development study in rats, bempedoic acid was given orally to male and female rats at 10, 30 and 60 mg/kg/day. Males were dosed for 28 days prior to mating and females were dosed 14 days prior to mating through gestation day 7. No adverse effects on fertility were observed in females in the absence of maternal toxicity. No effects were observed on male fertility outcomes, but decreases in sperm counts were observed at 60 mg/kg/day (9 times the MRHD).

14 CLINICAL STUDIES

14.1 Cardiovascular Outcomes Trial in Adults With CVD or at High Risk for CVD

Trial 1 (NCT02993406) was a randomized, double-blind, placebo-controlled, event-driven trial in 13,970 adult patients with established CVD (70%) or at high risk for a CVD event but without CVD (30%) who were not receiving recommended statin dosages. Patients with established CVD had documented history of coronary artery disease, symptomatic peripheral arterial disease, and/or cerebrovascular atherosclerotic disease. Patients without established CVD were considered at high risk for CVD based on meeting at least one of the following criteria:

- (1) Diabetes mellitus (type 1 or type 2) in females over 65 years of age or males over 60 years of age;
- (2) A Reynolds Risk score > 30% or a SCORE Risk score > 7.5% over 10 years. Reynolds risk score and SCORE risk score evaluate a 10-year risk of having a cardiovascular (CV) event. The Reynolds risk score is based on the following risk factors: sex, age, smoking status, systolic blood pressure, total cholesterol, HDL cholesterol, high sensitivity C-reactive protein (hsCRP), and familial history of CVD events. LDL-C is an additional risk factor considered in SCORE risk score; or
- (3) A coronary artery calcium score >400 Agatston units at any time in the past.

Patients were randomized 1:1 to receive either oral NEXLETOL 180 mg per day (n = 6,992) or placebo (n = 6,978), alone or as an add on to other background lipid-lowering therapies. Background therapy could include less than low-intensity statin dosages. Overall, 95.3% of adult patients were followed until the end of the trial or death. The median follow-up duration was 3.4 years.

Baseline Demographics and Disease Characteristics

At baseline, the mean age was 66 years (range 21 to 92 years), 59% were 65 years of age and older, 15% were 75 years of age and older, 48% were female, 91% were White, 2% were Black or African American, 4% were American Indian or Alaska Native, 2% were Asian, and 1% were other races; 17% identified as Hispanic or Latino ethnicity.

Selected additional baseline characteristics included hypertension (85%), diabetes mellitus (46%), current tobacco user (22%), eGFR < 60 mL/min per 1.73 m² (21%), and a mean body mass index of 30 kg/m². The mean baseline LDL-C was 139 mg/dL. At baseline, 38% of patients were taking at least one lipid-modifying therapy, including less than low-intensity statin dosages (23%), ezetimibe (12%), or fibrates (5%). Most patients were taking at least one other CV medication including acetylsalicylic acid (57%), selective beta blockers (52%), angiotensin converting enzyme inhibitors (40%), or angiotensin receptor blockers (32%).

Efficacy Results

The risk for the primary composite endpoint (MACE-4: time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization; p= 0.0037) and the key secondary composite endpoint (MACE-3: time to first occurrence of CV death, nonfatal myocardial infarction, or nonfatal stroke; p= 0.0058) was significantly reduced in NEXLETOL-treated patients compared to placebo-treated patients (see Table

4). The difference between the NEXLETOL and placebo groups in mean percent change in LDL-C from baseline to Month 6 was -20% (95% CI: -21%, -19%).

Table 4: Major Cardiovascular Events in Adults with Established CVD or at High Risk for CVD (Trial 1)


Endpoint	NEXLETOL N=6,992	Placebo N=6,978	NEXLETOL vs. Placebo
	n (%)	n (%)	Hazard Ratio (95% CI)
Primary Composite Endpoint			
Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization (MACE-4)	819 (11.7)	927 (13.3)	0.87 (0.79, 0.96)
Key Secondary Endpoint			
Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke (MACE-3)	575 (8.2)	663 (9.5)	0.85 (0.76, 0.96)
Components of Primary Composite Endpoint			
Non-fatal myocardial infarction	236 (3.4)	317 (4.5)	0.73 (0.62, 0.87)
Coronary revascularization	435 (6.2)	529 (7.6)	0.81 (0.72, 0.92)
Non-fatal stroke	119 (1.7)	144 (2.1)	0.82 (0.64, 1.05)
Cardiovascular death	269 (3.8)	257 (3.7)	1.04 (0.88, 1.24)

CI = confidence interval; MACE = major adverse cardiac event.

^aHazard ratio and corresponding 95% CI were based on a Cox proportional hazard model fitting treatment as explanatory variable. This table also presents the time to first occurrence for each of the components of MACE-4; patients may have been included in more than one category

The Kaplan-Meier estimates of the cumulative incidence of the MACE-4 and MACE-3 endpoints are shown in Figure 1 and 2 below.

Figure 1: Cumulative Incidence of Primary Composite Endpoint (MACE-4) Over 4.5 Years in Adults with Established CVD or at High Risk for CVD (Trial 1)




	No. at Risk									
NEXLETOL	6992	6816	6652	6472	6291	6105	5239	2594	1236	553
Placebo	6978	6779	6573	6401	6205	5993	5087	2513	1204	513

MACE = major adverse cardiac event

MACE-4 was defined as the time to first occurrence of the composite endpoint of CV death, nonfatal MI, nonfatal stroke, or coronary revascularization.

Figure 2: Cumulative Incidence of Composite Endpoint (MACE-3) Over 4.5 Years in Adults with Established CVD or at High Risk for CVD (Trial 1)



	No. at Risk									
NEXLETOL	6992	6859	6743	6604	6456	6297	5435	2717	1311	588
Placebo	6978	6828	6677	6536	6368	6191	5304	2638	1276	554

MACE = major adverse cardiac event

MACE-3 was defined as time to first occurrence of the composite endpoint of CV death, nonfatal MI, or nonfatal stroke.

14.2 Primary Hyperlipidemia Trials in Adults

The efficacy of NEXLETOL as an adjunct to diet and statin therapy, to reduce elevated LDL-C in adults with primary hyperlipidemia (including HeFH) was investigated in two multi-center, randomized, double-blind, placebo-controlled trials that enrolled 3,009 adult patients with HeFH or established CVD who were on maximally tolerated statin therapy (Trials 2 and 3). Demographics and baseline disease characteristics were balanced between the treatment arms in these trials. In both trials, the maximum LDL-C lowering effects occurred at Week 4. These results were consistent across all subgroups studied in any of the trials, including age, sex, race, ethnicity, region, history of diabetes, baseline LDL-C, body mass index (BMI), HeFH status, and background therapies.

Trial 2 (NCT02666664)

Trial 2 was a multi-center, randomized, double-blind, placebo-controlled, primary hyperlipidemia (52-week) trial in adult patients with HeFH and/or CVD. Efficacy of NEXLETOL was evaluated at Week 12. The trial included 2,230 patients randomized 2:1 to receive either oral NEXLETOL (n = 1,488) or placebo (n = 742) as add-on to a maximally tolerated lipid-lowering therapy. Maximally tolerated lipid-lowering therapy was defined as a maximally tolerated statin dose alone or in combination with other lipid-lowering therapies. Patients were stratified by presence of HeFH and by baseline statin intensity. Patients on simvastatin 40 mg per day or higher and patients taking PCSK9 inhibitors were excluded from the trial.

Baseline Demographics and Disease Characteristics: Overall, the mean age at baseline

was 66 years (range: 24 to 88 years), 61% were 65 years of age and older, 27% were female, 96% were White, 3% were Black or African American, and 1% were Asian; 2% identified as Hispanic or Latino ethnicity. Ninety-five percent (95%) of patients had established CVD, and 5% of patients had HeFH. Twenty-nine percent (29%) of patients had diabetes at baseline. The mean baseline LDL-C was 103.2 mg/dL. At the time of randomization, all patients were receiving statin therapy and 50% were receiving high-intensity statin therapy.

Efficacy Results: The primary efficacy outcome measure of the trial was the percent change from baseline to Week 12 in LDL-C. The difference between the NEXLETOL and placebo groups in mean percent change in LDL-C from baseline to Week 12 was -18% (95% CI: -20%, -16%; $p < 0.001$). High-density lipoprotein (HDL) and triglycerides (TG) were examined as exploratory endpoints and were not included in the statistical hierarchy. The difference between the NEXLETOL and placebo groups in mean percent change from baseline to Week 12 was -6% for HDL and median percent change from baseline to Week 12 was +3% for TG. For additional results see Table 4 and Figure 3.

Table 4: Lipid Parameters in Adult Patients with HeFH and/or CVD on Maximally Tolerated Statin Therapy (Mean % Change from Baseline to Week 12 in Trial 2)

	LDL-C ^{*,†}	Non-HDL-C [†]	apo B [†]	TC [†]
NEXLETOL (180 mg/day; n = 1488 [‡])	-17	-12	-9	-10
Placebo (n = 742 [‡])	2	2	3	1
Mean Difference from Placebo (95% CI)	-18 (-20, -16)	-13 (-15, -12)	-12 (-14, -10)	-11 (-13, -10)

apo B = apolipoprotein B; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TC = total cholesterol.

Background statin: atorvastatin, simvastatin, pravastatin, and/or other lipid-lowering therapies

* 4.3% of subjects on NEXLETOL and 2.3% of patients on placebo had missing LDL-C data at primary endpoint (Week 12). By the end of the trial (Week 52), 8.3% of patients on NEXLETOL and 7.7% of patients on placebo had missing LDL-C measurements.

† Percent change from baseline was analyzed using analysis of covariance (ANCOVA), with treatment and randomization strata (HeFH versus CVD, and high intensity statin versus other statin) as factors and baseline lipid parameter as a covariate. Missing data for LDL-C, non-HDL-C, TC and apo B were imputed through multiple imputation using a pattern mixture model (PMM) account for treatment adherence.

‡ Number of randomized subjects at baseline

Trial 3 (NCT02991118)

Trial 3 was a multi-center, randomized, double-blind, placebo-controlled, primary hyperlipidemia (52-week) trial in patients with HeFH and/or CVD. Efficacy of NEXLETOL

was evaluated at Week 12. The trial included 779 patients randomized 2:1 to receive either oral NEXLETOL (n = 522) or placebo (n = 257) as add-on to a maximally tolerated lipid-lowering therapy. Maximally tolerated lipid-lowering therapy was defined as a maximally tolerated statin dose alone or in combination with other lipid-lowering therapies. Patients were stratified by presence of HeFH and baseline statin intensity. Patients on simvastatin 40 mg/day or higher were excluded from the trial.

Baseline Demographics and Disease Characteristics: Overall, the mean age at baseline was 64 years (range: 28 to 91 years), 51% were 65 years of age and older, 36% were female, 94% were White, 5% were Black or African American, and 1% were Asian; 8% identified as Hispanic or Latino ethnicity. Ninety-five percent (95%) of patients had established CVD, and 5% of patients had HeFH. Thirty percent (30%) of patients had diabetes at baseline. The mean baseline LDL-C was 120.4 mg/dL. At the time of randomization, 90% of patients were receiving statin therapy, 53% were receiving high-intensity statin therapy, and 0.3% were receiving PCSK9 inhibitors.

Efficacy Results: The primary efficacy outcome measure of the trial was the percent change from baseline to Week 12 in LDL-C. The difference between the NEXLETOL and placebo groups in mean percent change in LDL-C from baseline to Week 12 was -17% (95% CI: -21%, -14%; p < 0.001). HDL and TG were exploratory endpoints and not included in the statistical hierarchy. The difference between the NEXLETOL and placebo groups in mean percent change from baseline to Week 12 was -6% for HDL and the median percent change from baseline was -2% for TG. For additional results see Table 5 and Figure 3.

Table 5. Lipid Parameters in Adult Patients with HeFH and/or CVD on Maximally Tolerated Statin Therapy (Mean % Change from Baseline to Week 12 in Trial 3)

	LDL-C*,†	Non-HDL-C†	apo B†	TC†
NEXLETOL (180 mg/day; n = 522‡)	-15	-11	-9	-10
Placebo (n = 257‡)	2	2	4	1
Difference from Placebo (95% CI)	-17 (-21, -14)	-13 (-16, -10)	-13 (-16, -10)	-11 (-14, -9)

apo B = apolipoprotein B; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TC = total cholesterol.


Background statin: atorvastatin, simvastatin, rosuvastatin, pravastatin, fluvastatin, pitavastatin, and lovastatin ± other lipid-lowering therapies

* 4.6% of patients on NEXLETOL and 1.6% of patients on placebo had missing LDL-C data at primary endpoint (Week 12). By the end of the trial (Week 52), 10.5% of patients on NEXLETOL and 7.8% of patients on placebo had missing LDL-C measurements.

† Percent change from baseline was analyzed using analysis of covariance (ANCOVA), with treatment and randomization strata (HeFH versus CVD, and high intensity statin versus other statin) as factors and baseline lipid parameter as a covariate. Missing data for LDL-C, non-HDL-C, TC and apo

B were imputed through multiple imputation using a pattern mixture model (PMM) account for treatment adherence.
 ‡ Number of randomized patients at baseline

Figure 3: Mean Percent Change from Baseline in LDL-C Over 52 Weeks in Adult Patients with HeFH and/or CVD on Maximally Tolerated Statin Treated with NEXLETOL or Placebo (Trial 2 and Trial 3)



No. of Subjects (n)

NEXLETOL 180 mg	2010	1934	1922	1882	1491	1831
Placebo	999	980	978	954	756	922

LDL-C derived is calculated from the Friedewald equation: $LDL-C = TC - HDL-C - TG/5$ in mg/dL.

The error bars represent standard error.

16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

NEXLETOL tablets are supplied as follows:

Tablet Strength	Description	Package Configuration	NDC No.
180 mg	White to off white and oval, debossed with "180" on one side and "ESP" on the other side	Bottle of 30 tablets with child-resistant cap	72426-118-03
		Bottle of 90 tablets with child-resistant cap	72426-118-09

Storage and Handling

Store at 68°F to 77°F (20°C to 25°C); excursions permitted to 59°F to 86°F (15°C to 30°C) [see USP Controlled Room Temperature]. Store and dispense in the original package.

17 PATIENT COUNSELING INFORMATION

Advise patients to read the FDA-approved patient labeling (Patient Information).

Risk of Hyperuricemia

Advise patients of the risk of elevated serum uric acid levels, including development of gout. Inform patients that serum uric acid levels may be monitored during treatment with NEXLETOL. Patients with signs or symptoms of hyperuricemia should contact their healthcare provider if symptoms occur [See Warnings and Precautions (5.1)]

Risk of Tendon Rupture

Inform patients of the risk of tendon rupture. Advise patients to rest at the first sign of tendinitis or tendon rupture and to immediately contact their healthcare provider if tendinitis or tendon rupture symptoms occur [see Warnings and Precautions (5.2)].

Risk of Myopathy with Concomitant Use of Simvastatin or Pravastatin

Advise patients to notify their healthcare provider(s) if they are taking, or plan to take simvastatin or pravastatin. The risk of myopathy occurring with the use of simvastatin or pravastatin may be increased when taken with NEXLETOL [see Drug Interactions (7)].

Pregnancy

Advise pregnant women of the potential risk to a fetus based on NEXLETOL's mechanism of action. Advise females to inform their healthcare provider of a known or suspected pregnancy. Advise patients that there is a pregnancy safety study that monitors pregnancy outcomes in patients exposed to NEXLETOL during pregnancy. Encourage these patients to report their pregnancy to Esperion at 1-833-377-7633 [see Use in Specific Populations (8.1)].

Manufactured for:

Esperion Therapeutics, Inc.
3891 Ranchero Drive, Suite 150
Ann Arbor, MI 48108

NEXLETOL® (bempedoic acid) tablets
© 2024 Esperion Therapeutics, Inc.

<p>PATIENT INFORMATION NEXLETOL® (NEX-le-tol) (bempedoic acid) tablets, for oral use</p>
--

What is NEXLETOL?

NEXLETOL is a prescription medicine used:

- to lower the risk of heart attack and heart procedures like stent placement or bypass surgery, in adults who are unable to take recommended statin treatment (a cholesterol-lowering medicine), or are not taking a statin, who:

- have known heart disease, or
- are at high risk for heart disease but without known heart disease.
- along with diet and other cholesterol-lowering medicines, or alone when use with other cholesterol-lowering medicines is not possible, to reduce low-density lipoprotein (LDL, or bad cholesterol) in adults with high blood cholesterol levels called primary hyperlipidemia, including a type of high blood cholesterol called heterozygous familial hypercholesterolemia (HeFH).

It is not known if NEXLETOL is safe and effective in children.

Do not take NEXLETOL if you are allergic to bempedoic acid or any of the ingredients in NEXLETOL. See the end of this leaflet for a complete list of ingredients in NEXLETOL. Stop taking NEXLETOL and call your healthcare provider or go to the nearest hospital emergency room right away if you have any signs or symptoms of an allergic reaction including:

- swelling of your face, lips, mouth or tongue
- wheezing
- severe itching
- fast heart beat or pounding in your chest
- trouble breathing
- skin rashes, redness, or swelling
- dizziness or fainting

Before you start taking NEXLETOL, tell your healthcare provider about all your medical conditions, including if you:

- have or had gout.
- have or had tendon problems.
- are pregnant or think you may be pregnant. Tell your healthcare provider right away if you become pregnant while taking NEXLETOL. You and your healthcare provider will decide if you should take NEXLETOL while you are pregnant. If you are pregnant during NEXLETOL treatment, you are encouraged to call Esperion at 1-833-377-7633 to share information about the health of you and your baby.
- are breastfeeding or plan to breastfeed. It is not known if NEXLETOL passes into your breast milk. You and your healthcare provider should decide if you will take NEXLETOL or breastfeed. You should not do both.
- have severe kidney problems.
- have severe liver problems.

NEXLETOL may affect the way other medicines work, and other medicines may affect how NEXLETOL works. **Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.**

Especially tell your healthcare provider if you take or plan to take simvastatin or pravastatin (other cholesterol-lowering medicines). Taking simvastatin or pravastatin with NEXLETOL may increase your risk of developing muscle pain or weakness (myopathy).

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I take NEXLETOL?

- Take NEXLETOL exactly as your healthcare provider tells you to take it. Check with your healthcare provider or pharmacist if you are not sure.

- Take 1 NEXLETOL tablet by mouth each day.
- You may take NEXLETOL with or without food.
- Your healthcare provider may do blood tests to check your LDL-C levels between 8 to 12 weeks after starting treatment with NEXLETOL.
- In case of overdose, get medical help or contact a live Poison Center expert right away at 1-800-222-1222. Advice is also available online at poisonhelp.org.

What are possible side effects of NEXLETOL?

NEXLETOL may cause serious side effects, including:

- **increased levels of uric acid in your blood (hyperuricemia).** This can happen within 4 weeks of you starting NEXLETOL and continue throughout your treatment. Your healthcare provider may monitor your blood uric acid levels while you are taking NEXLETOL. High levels of blood uric acid may lead to gout. Call your healthcare provider if you have the following symptoms of hyperuricemia and gout:
 - severe foot pain especially in the toe joint
 - warm joints
 - swelling
 - tender joints
 - joint redness
- **tendon rupture or injury. Tendon problems can happen in people who take NEXLETOL.** Tendons are tough cords of tissue that connect muscles to bones. Symptoms of tendon problems may include pain, swelling, tears, and inflammation of tendons, most commonly with the rotator cuff (the shoulder), the biceps tendon (upper arm), and Achilles tendon at the back of the ankle. This can also happen with other tendons. Tendon ruptures can happen within weeks or months of starting NEXLETOL.
 - **The risk of getting tendon problems while you take NEXLETOL is higher if you:**
 - are over 60 years of age
 - are taking antibiotics (fluoroquinolones)
 - are taking steroids (corticosteroids)
 - have renal failure
 - have had tendon problems
 - **Stop taking NEXLETOL immediately and get medical help right away if you get any of the following signs or symptoms of a tendon rupture:**
 - hear or feel a snap or pop in a tendon area
 - bruising right after an injury in a tendon area
 - unable to move the affected area or put weight on the affected area
 Avoid exercise and using the affected area.

The most common side effects of NEXLETOL in people with primary hyperlipidemia include:

- symptoms of the common cold, flu, or flu-like symptoms
- muscle spasms
- back pain
- stomach pain
- bronchitis
- pain in shoulder, legs, or arms
- anemia
- increased liver enzymes

The most common side effects of NEXLETOL in people with heart problems include:

- kidney problems
- anemia
- increased liver enzymes
- muscle spasms
- gallstones

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of NEXLETOL.

For more information, ask your healthcare provider or pharmacist. **Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.**

How should I store NEXLETOL?

- Store NEXLETOL in the original package at room temperature between 68°F to 77°F (20°C to 25°C).

Keep NEXLETOL and all medicines out of the reach of children.

General information about the safe and effective use of NEXLETOL.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. **Do not** use NEXLETOL for a condition for which it was not prescribed. **Do not** give NEXLETOL to other people, even if they have the same symptoms that you have. It may harm them.

You can ask your pharmacist or healthcare provider for information about NEXLETOL that is written for healthcare professionals.

What are the ingredients in NEXLETOL?

- **active ingredient:** bempedoic acid
- **inactive ingredients:** colloidal silicon dioxide, hydroxyl propyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate
- **tablet coating:** partially hydrolyzed polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide

Manufactured for:

Esperion Therapeutics, Inc.
3891 Ranchero Drive, Suite 150
Ann Arbor, MI 48108

© 2024 Esperion Therapeutics, Inc.

This Patient Information has been approved by
the U.S. Food and Drug Administration

Revised: 03/2024

PRINCIPAL DISPLAY PANEL - 180 mg Tablet Bottle Label

NDC 72426-118-03

Rx only

NEXLETOL®
(bempedoic acid) tablets

Contains
30 Tablets

180 mg

Storage: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original package.

Dosage and Administration: See accompanying Package Insert for Full Prescribing Information. Each tablet contains 180 mg bempedoic acid. Made in India

Manufactured for:
Esperion Therapeutics, Inc., Ann Arbor, MI 48108
ESPERION

NDC 72426-118-03 Rx only

NEXLETOL[®]
(bempedoic acid) tablets

Contains
30 Tablets

180 mg

611926119



NEXLETOL

bempedoic acid tablet, film coated

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:72426-118
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
BEMPEDOIC ACID (UNII: 1EJ6Z6Q368) (BEMPEDOIC ACID - UNII:1EJ6Z6Q368)	BEMPEDOIC ACID	180 mg

Inactive Ingredients

Ingredient Name	Strength
MICROCRYSTALLINE CELLULOSE 101 (UNII: 7T9FYH5QMK)	
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)	
HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 9XZ8H6N6OH)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
POLYVINYL ALCOHOL, UNSPECIFIED (UNII: 532B59J990)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	
POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)	
TALC (UNII: 7SEV7J4R1U)	

Product Characteristics

Color	WHITE (White to off-white)	Score	no score
Shape	OVAL	Size	14mm
Flavor		Imprint Code	180;ESP
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:72426-118-03	30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	03/06/2020	
2	NDC:72426-118-09	90 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	03/06/2020	
3	NDC:72426-118-99	7 in 1 BLISTER PACK; Type 0: Not a Combination Product	03/06/2020	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA211616	03/06/2020	

Labeler - Esperion Therapeutics, Inc. (029516312)

Revised: 3/2024

Esperion Therapeutics, Inc.